Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTD/TPI + regorafenib vs FTD/TPI + bevacizumab in refractory metastatic colorectal cancer
ChiCTR2500102445Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in colorectal adenocarcinoma comparing Trifluridine-tipiracil + bevacizumab with Trifluridine-tipiracil + regorafenib (2 arms). Primary endpoint: Progression-free survival. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilregorafenibbevacizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500102445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102445.